<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000341.v2.p1" parentStudy="phs000341.v2.p1" createDate="2012-10-01" modDate="2013-02-07">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Charles Mullighan, MBBS(Hons), MSc, MD</td><td>Dept. of Pathology, St. Jude Children&#39;s Research Hospital, Memphis, TN, USA</td></tr>
		<tr><td>Funding Source</td><td>NCI RC4CA156329 &quot;Identifying the spectrum of genetic alterations in high risk acute leukemia&quot;</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>The Genetic Basis of Hypodiploid ALL</StudyNameEntrez>
	<StudyNameReportPage>The Genetic Basis of Hypodiploid ALL</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
		<StudyType>Tumor vs. Matched-Normal</StudyType>
		<StudyType>Xenograft</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases, including whole-genome and exome sequencing of 40 cases, identified two subtypes that differ in the severity of aneuploidy, transcriptional profiles and submicroscopic genetic alterations. Near-haploid ALL with 24-31 chromosomes harbor alterations targeting receptor tyrosine kinase signaling and Ras signaling (71%) and the lymphoid transcription factor gene IKZF3 (encoding AIOLOS; 13%). In contrast, low-hypodiploid ALL with 32-39 chromosomes are characterized by alterations in TP53 (91.2%) that are commonly present in nontumor cells, IKZF2 (encoding HELIOS; 53%) and RB1 (41%). Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Primary pediatric and adult acute lymphoblastic leukemia cases with material available for genome-wide profiling.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23334668"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Precursor Cell Lymphoblastic Leukemia-Lymphoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Charles Mullighan, MBBS(Hons), MSc, MD</AttName>
			<Institution>Dept. of Pathology, St. Jude Children&#39;s Research Hospital, Memphis, TN, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>NCI RC4CA156329 &quot;Identifying the spectrum of genetic alterations in high risk acute leukemia&quot;</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>Whole genome sequencing, whole exome sequencing and SNP 6.0 profiling of DNA copy number alterations was performed on primary human tumors and matched normal DNA.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000341.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000341.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000341.v2.p1" FileName="DUC-GWA_of_Genetic_Alterations_in_Hypodiploid_ALL-Revised_2.4.11.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data set is limited to research purposes only.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
